Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at Crown Promenade in Melbourne.
The Australia Biologics Festival aims to gather the innovators, pioneers and leaders in the biologics industry, including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics, to showcase the latest technologies from ideation to commercialisation phase and beyond.
Dr Nisbet’s presentation entitled, Driving Next Generation Cell Therapies with CAR-T/NK Cell Manufacturing, will take place on Wednesday 21st February at 1.30pm (AEDT). The presentation will describe Cartherics’ approach to establishing and developing its cell therapy platform, with a focus on:
- Next generation cell therapy treatment alternatives
- Development, CMC and regulatory considerations in Australia
- Strategies for manufacturing engineered T-cells/NK-cells for better efficacy
Cartherics’ lead allogeneic cell therapy, CTH-401, has shown excellent efficacy in animal models and first-in-human clinical trials are planned for 2025. The method of manufacture for CTH-401 includes a number of proprietary features and provides for cost-effective, scalable manufacturing. As an “off-the-shelf” product, CTH-401 offers convenient, on-demand treatment for patients.
Cartherics also has an autologous (patient-derived) cell therapy (CTH-004) for ovarian cancer that is due to enter clinical trials in Australia and China in 2024/25.
Dr Nisbet said: “Cartherics was founded as a concept, with no technology, no IP and no money. I am delighted to be able to tell conference attendees how we built the company and its cell therapy platform and share some of the important lessons we learned along the way.”
Dr Nisbet was recently interviewed by IMAPAC discussing key trends and innovative developments in Australia’s biopharmaceutical industry. Read it here: https://cartherics.com/wp-content/uploads/2024/01/ABF24_-Speaker-Interview_IN.pdf